CoreMedic GmbH is an innovative medical technology company based in Radolfzell, Germany, specializing in the development of minimally invasive therapies for heart valve diseases. As a spin-off of the Heart and Vascular Center of the University of Bern, CoreMedic was founded in 2012 to develop new treatment approaches for mitral valve regurgitation (Mitral Valve Regurgitation, MR) – a widespread and serious heart disease that affects over 24 million people worldwide.
CoreMedic's core product is the revolutionary ChordArtâ„¢-System, a transcatheter-based procedure for repairing the mitral valve on the beating heart. In contrast to conventional open-heart surgery, ChordArt enables the minimally invasive, trans-femoral implantation of artificial chordae tendineae (Chordae) that replace damaged valve structures. This innovative technology reduces patient risk, shortens surgery and recovery time, and makes treatment accessible to patients who are not suitable for conventional surgery.
CoreMedic pursues a clear mission: to significantly improve the care of patients with heart valve disease through groundbreaking, safe and effective therapies, while minimizing the burden on patients and healthcare. In addition to medical innovation, the company relies on interdisciplinary collaboration and an international network of cardiac surgeons, cardiologists and experts from research and regulation.
In the area of sustainability, CoreMedic is committed to developing efficient and patient-oriented therapy solutions that reduce resource consumption and hospital days. The company is certified according to the international standard EN ISO 13485:2016, which underscores high standards in medical device quality management.
To further promote clinical development, CoreMedic strategically collaborates with partners such as InnoRa GmbH to advance innovations technically and regulatorily, thereby expanding treatment options for patients with mitral valve disease in the long term.
In summary, CoreMedic is a pioneering company for state-of-the-art, minimally invasive heart valve therapies, which, with technological excellence, clinical focus and sustainable health benefits, is one of the pioneers in cardiology.
